The N6 Adenosine Methyltransferase Catalytic Subunit pipeline drugs market research report outlays comprehensive information on the N6 Adenosine Methyltransferase Catalytic Subunit targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the N6 Adenosine Methyltransferase Catalytic Subunit pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, and Metabolic Disorders which include the indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Parkinson’s Disease, Anxiety Disorders, and Type 2 Diabetes. It also reviews key players involved in N6 Adenosine Methyltransferase Catalytic Subunit targeted therapeutics development with respective active and dormant or discontinued products.
The N6 Adenosine Methyltransferase Catalytic Subunit pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 3, and 2 respectively.
N6 Adenosine Methyltransferase Catalytic Subunit overview
N6 Adenosine Methyltransferase Catalytic Subunit (METTL3) is an enzyme that plays a crucial role in regulating gene expression by modifying RNA molecules. It is responsible for adding a methyl group to the nitrogen 6 position of adenosine (A), resulting in the formation of N6-methyladenosine (m6A). m6A is the most abundant internal modification of messenger RNA (mRNA) and is involved in various biological processes, including mRNA stability, splicing, translation, and decay.
For a complete picture of N6 Adenosine Methyltransferase Catalytic Subunit’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
